Oncotarget

Exploring the therapeutic potential of humanized JAA-F11 anti-Thomsen-Friedenreich antibodies H2aL2a and H3L3 in human breast and lung cancer xenograft models. Study shows H2aL2a significantly decreases tumor growth in both cancer types, with H3L3 showing higher affinity but potentially less tumor penetration. Research by Diala Ghazal, Fatma Zalzala, and collaborators aims to assess the therapeutic efficacy of these antibodies in treating various cancer mouse xenograft models.

Discusses the role of PDGF in colorectal cancer and its potential as a target for combination therapy. Researchers found upregulation of PDGFRβ, VEGFR1, and VEGFR2 genes in colon tumors. Immunohistological analysis showed co-expression of PDGF in tumor stroma.

Explore the synergy of HDAC inhibitors, PARP inhibitors, and chemotherapeutics in blood cancer treatment. Learn how inhibiting PARylation can enhance sensitivity to treatment and potentially improve hematologic cancer therapy.

Researchers Michael Jonathan Kucharczyk, Andrew Bang, and Michael C. Tjong discuss the impact of radiotherapy on local control for T3N0 rectal cancer patients post surgery, revealing that it may not significantly reduce the risk of local regional recurrence. They emphasize the importance of unbiased trial data for better treatment decisions.

Researcher Liza A. Wijler discusses how specific nutrients like EPA, DHA, L-leucine, and vitamin D3 can help mitigate chemotherapy-associated muscle toxicity in colorectal cancer patients. The study focused on maintaining treatment efficacy while protecting muscle cells from the negative impact of chemotherapy.

Exploring synthetic lethality in genetic interactions for personalized cancer therapy, researchers used CRISPR screens to identify potential targets based on PARP-10 expression levels in cancer cells. Results revealed key genes essential for viability of PARP-10 knockout cells, offering insights into precision oncology approaches.

Researchers Crystal S. Seldon, Karthik Meiyappan, Hannah Hoffman, and others discussed genomic alterations in pan-cancer predicting poor clinical outcomes. They explored associations of common genomic alterations across 28 cancers, emphasizing the importance of tailored treatment strategies for patients with specific genomic alterations.

Exploring challenges in predicting Nivolumab response in an HIV-positive anal cancer patient with MSI, emphasizing molecular analysis for tailored treatment decisions.

High altitudes influence various physiological processes like HIF-1 expression and vitamin D levels, impacting diseases like gastric cancer. GA incidence is higher at high altitudes due to hypoxia-induced HIF-1 activation. Understanding the role of HIF-1 in GA pathogenesis and prognosis is crucial for high-altitude populations.

Exploring the protein-based risk model for esophageal cancer recurrence, researchers identify biomarkers to improve treatment outcomes. Four prognostic molecular signatures show promise in predicting disease recurrence and stratifying patients based on risk levels.